Aadi Bioscience price target lowered to $45 from $48 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Aadi Bioscience to $45 from $48 and keeps a Buy rating on the shares following the Q4 results. The firm took higher operating expenses into account.